Citigroup Downgrades Moderna to Sell, Raises Price Target to $80

Benzinga · 1d ago
Citigroup analyst Geoff Meacham downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $60 to $80.